Read the consensus statement
 
    Medtronic
 
   
 
 
The position
is clear.
 
New ESC-EAPCI consensus statement recommends renal denervation for uncontrolled resistant hypertension.†1
 
 
 
 
   
 
A new consensus statement from the European Society of Cardiology (ESC) Council on Hypertension and European Association of Percutaneous Cardiovascular Interventions (EAPCI) recommends renal denervation as a safe and effective complementary treatment strategy.1
 
 
 
 
Renal denervation
The third pillar for hypertension management1
 
 
 
Lifestyle
modifications
 
 
Medications
 
 
Renal
denervation
 
 
 
 
   
   
Transforming hypertension treatment
 
The Symplicity™ blood pressure procedure is proven to provide significant, safe and sustained blood pressure reduction in the presence and absence of medications.‡2-7
 
 
Adverse events include, but are not limited to, pain and hematoma. Results may vary. See the Symplicity Spyral™ IFU for more info.
 
 
>18 mmHg reduction in OSBP at 3 years in presence of meds[6,7]
 
   
 
Receive the latest updates and clinical data about the Symplicity blood pressure procedure.
 
 
   
   
 
References
 
† Resistant hypertension is defined as uncontrolled office BP (≥140/≥90 mmHg), which is confirmed by out-of-office BP measurements, despite appropriate lifestyle changes and the intake of a triple-drug combination, including a diuretic at maximally tolerated doses.
 
‡ Safe and sustained blood pressure reduction in the absence of medications demonstrated in the SPYRAL HTN-OFF MED study at 3 months.
 
1. Barbato E, Mahfoud F, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. Published online Feb. 15, 2023.
 
2. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-1451. doi:10.1016/S0140-6736(20)30554-7
 
3. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160-2170. doi:10.1016/S0140-6736(17)32281-X
 
4. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-2355. doi:10.1016/S0140-6736(18)30951-6
 
5. Kandzari DE, et al, Renal denervation in the presence of anti-hypertensive medications: six-month results from the randomized, blinded, sham-controlled SPYRAL HTN-ON MED trial. Presented at AHA 2022.
 
6. Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 2022; 399: 1401–10.
 
7. Schlaich M, Bohm M, Mahfoud F, et al. Long-term safety and efficacy of renal denervation with the Symplicity Spyral catheter in the Global SYMPLICITY Registry. Presented at Kidney Week 2021.
 
in   t
 
Medtronic
 
Medtronic.eu/Symplicity
 
UC202303093 EE ©2023 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan, or France.